Patent assignee · US · COMPANY

NantCell, Inc.

42Patents
41Active
42Granted
58Portfolio score

Filing activity: Jan 25, 2017 → Apr 22, 2025

Most-cited patents

PatentTitleAreaCited byStatus
US11364291B1 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer Human Necessities 3 Active
US11207392B2 Coordinated multi-prong cancer therapy Chemistry; Metallurgy 3 Active
US11554167B2 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer Human Necessities 3 Active
US11701408B2 Treatment of immunosuppressed subjects Emerging Cross-Sectional Technologies 2 Active
US11948687B2 Deep learning models for region-of-interest determination Physics 2 Active
US11311603B2 HIV treatment compositions and methods Emerging Cross-Sectional Technologies 2 Active
US11229668B2 Maximizing T-cell memory and compositions and methods therefor Chemistry; Metallurgy 2 Active
US11779637B2 Targeted neoepitope vectors and methods therefor Emerging Cross-Sectional Technologies 1 Active
US12016911B2 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer Human Necessities 1 Active
US11857612B2 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer Human Necessities 1 Active
US11071774B2 Nant cancer vaccine Chemistry; Metallurgy 1 Active
US10973852B2 NK cells with altered CXCL12/CXCR4 signaling Chemistry; Metallurgy 1 Active
US11894109B1 Production and delivery tracking and sample verification of patient-specific therapeutics Physics 1 Active
US11662938B2 Object storage and access management systems and methods Electricity 1 Active
US12156901B2 Treatment of immunosuppressed subjects Emerging Cross-Sectional Technologies 1 Active
US12285480B2 Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses Chemistry; Metallurgy 0 Active
US12297247B2 Fusion molecules of CTLA4 and IL-15 Chemistry; Metallurgy 0 Active
US12112838B2 Production and delivery tracking and sample verification of patient-specific therapeutics Physics 0 Active
US11684668B2 Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence Chemistry; Metallurgy 0 Active
US12427184B2 Treatment of immunosuppressed subjects Emerging Cross-Sectional Technologies 0 Active
US12224064B2 Deep learning models for tumor evaluation Physics 0 Active
US12050802B2 Object storage and access management systems and methods Electricity 0 Active
US12168048B2 Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer Human Necessities 0 Active
US12224066B2 Deep learning models for region of interest determination Physics 0 Active
US11364265B1 Recombinant erIL-15 NK cells Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.